Janssen Vaccines
biotechnology subsidiary of Johnson & Johnson
Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell. Janssen Vaccines is part of Johnson & Johnson Innovative Medicine business segment.
History
In 1993 Introgene, Crucell's predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.
The public source identifies “Janssen Vaccines” as biotechnology subsidiary of Johnson & Johnson. This brief keeps that definition visible, then builds a research path around Janssen, Vaccines and biotechnology.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Janssen Vaccines”, the useful work is to connect “biotechnology subsidiary of Johnson & Johnson” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 11, 2026. The linked authority identifier is Q3005506. 3 of 3 selected statements include explicit references; 2 carry qualifiers and 1 use preferred rank. The first chronological checks are 1993, 1999, 2000 and 2006.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Janssen Vaccines”, its source revision and the description used here.
- Expand the search: follow Janssen Vaccines primary sources, Janssen Vaccines archive and Janssen research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Janssen Vaccines”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Janssen Vaccines” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.